Printer Friendly

SwRI & MBF Therapeutics sign exclusive licence for proprietary drug delivery system for animal health.

Global Banking News-May 10, 2019-SwRI & MBF Therapeutics sign exclusive licence for proprietary drug delivery system for animal health

(C)2019 ENPublishing -

Southwest Research Institute (SwRI) revealed on Thursday the launch of an exclusive licence agreement for its drug delivery system with MBF Therapeutics (MBFT).

The company has out licensed its patented calcium phosphate nanoparticle delivery system to develop its advanced immunotherapeutic treatments for canine melanoma MBF Therapeutics (MBFT).

Additionally, SwRI holds two US patents for its calcium phosphate nanoparticle (CaPNP) drug delivery system. The non-toxic, biocompatible drug delivery vehicle safely dissolves under specific conditions.

In conjunction with the agreement, MBFT will conduct clinical trials of an advanced immunotherapeutic vaccine to prevent and treat cancer in dogs and eventually other companion animals and livestock. MBF Therapeutics currently plans to incorporate SwRI's technology to develop vaccines for canine cancer therapeutics.

According to the company, more than 100,000 dogs are affected by canine melanoma every year.

((Distributed via M2 Communications -

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Date:May 10, 2019
Previous Article:Natera incurs higher net loss of USD34.1m for Q1 2019.
Next Article:PROTEOR USA appoints Matthew Swiggum as new president and CEO.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |